Bo Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Zhou has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Usha Sambamoorthi
University of North Texas Health, Fort Worth, TX, USA
4 shared publicationsNethra Sambamoorthi
University of North Texas Health, Fort Worth, TX, USA
3 shared publicationsYifan Zhang
University of North Texas Health, Fort Worth, TX, USA
3 shared publicationsAmit D. Raval
Bayer HealthCare Pharmaceuticals Whippany New Jersey USA
2 shared publications- Hao Wang
Department of Emergency Medicine, JPS Health Network, 1500 S. Main St., Fort Worth, TX 76104, USA
2 shared publications Matthew J. Korn
Bayer AG Dexter Michigan USA
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 2971
Association Between Baseline Glucagon-like Peptide-1 Receptor Agonist Use and Newly Documented Depression Diagnosis in Adults with Type 2 Diabetes: A Multi-State Medicaid Cohort Study
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM). However, its mental health safety profile in routine care, particularly among Medicaid beneficiaries, remains uncertain. We aim to examine the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and newly documented depression diagnosis among adults with type 2 diabetes mellitus (T2DM) enrolled in Medicaid. Methods: We conducted a retrospective longitudinal cohort study using the 2022–2023 Merative™ MarketScan® Multi-State Medicaid Database. Adults aged 18–64 years with T2DM, continuous Medicaid enrollment, and no documented depression during the 2022 baseline period were included. Baseline GLP-1 RA use was assessed in 2022, and newly diagnosed depression was identified in 2023. Associations were estimated using multivariable logistic regression, inverse probability weighting (IPW), and a doubly robust estimator. Results: Among 74,760 eligible adults, 14,953 (20.0%) were GLP-1 RA users. Incident depression occurred in 12.9% of users and 11.1% of non-users (absolute difference, 1.8 percentage points; p < 0.001). GLP-1 RA use was associated with higher odds of newly documented depression diagnosis in multivariable analysis (adjusted OR 1.10, 95% CI 1.04–1.16), IPW analysis (OR 1.09, 95% CI 1.03–1.15), and doubly robust analysis (OR 1.09, 95% CI 1.03–1.15). Conclusions: Baseline GLP-1 RA use was associated with modestly higher odds of a newly documented depression diagnosis during the subsequent year. Prospective studies are needed to determine whether this association is causal.
- 11 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 2971
Open AccessAssociation Between Baseline Glucagon-like Peptide-1 Receptor Agonist Use and Newly Documented Depression Diagnosis in Adults with Type 2 Diabetes: A Multi-State Medicaid Cohort Study
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM). However, its mental health safety profile in routine care, particularly among Medicaid beneficiaries, remains uncertain. We aim to examine the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and newly documented depression diagnosis among adults with type 2 diabetes mellitus (T2DM) enrolled in Medicaid. Methods: We conducted a retrospective longitudinal cohort study using the 2022–2023 Merative™ MarketScan® Multi-State Medicaid Database. Adults aged 18–64 years with T2DM, continuous Medicaid enrollment, and no documented depression during the 2022 baseline period were included. Baseline GLP-1 RA use was assessed in 2022, and newly diagnosed depression was identified in 2023. Associations were estimated using multivariable logistic regression, inverse probability weighting (IPW), and a doubly robust estimator. Results: Among 74,760 eligible adults, 14,953 (20.0%) were GLP-1 RA users. Incident depression occurred in 12.9% of users and 11.1% of non-users (absolute difference, 1.8 percentage points; p < 0.001). GLP-1 RA use was associated with higher odds of newly documented depression diagnosis in multivariable analysis (adjusted OR 1.10, 95% CI 1.04–1.16), IPW analysis (OR 1.09, 95% CI 1.03–1.15), and doubly robust analysis (OR 1.09, 95% CI 1.03–1.15). Conclusions: Baseline GLP-1 RA use was associated with modestly higher odds of a newly documented depression diagnosis during the subsequent year. Prospective studies are needed to determine whether this association is causal.
- 5 March 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 102, 103041
Accuracy of diagnostic codes to identify metastatic prostate cancer in medicare claims database
- 5 March 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 102, 103041
Accuracy of diagnostic codes to identify metastatic prostate cancer in medicare claims database
- 1 January 2026
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 32 (1) , 14-26
Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively reduce hypoglycemia and offer additional clinical benefits such as weight loss. However, their high costs impose a significant economic burden on both patients and payers. Health care expenditures associated with GLP-1 RA use have not been adequately examined in previous studies. To examine the excess expenditures (total, payer, and out-of-pocket) associated with GLP-1 RA use compared with nonuse among adults with diabetes in the United States. The study design was cross-sectional using data on adults (aged ≥18 years) with diabetes from multiple years (2016, 2018, and 2020) of the Medical Expenditure Panel Survey. Any GLP-1 RA use was derived from prescription medication files. Dependent variables included total, payer, and out-of-pocket health care expenditures. Excess expenditures associated with GLP-1 RAs were estimated using a multivariable generalized linear model (GLM) with gamma distribution and log link. The model adjusted for age, sex, race and ethnicity, social determinants of health, obesity, physical activity, and comorbid conditions. The study sample consisted of 7,670 adults with diabetes, representing approximately 28.6 million individuals in the United States. Overall, 7.5% of adults with diabetes used GLP-1 RAs, with rates increasing from 4.3% in 2016 to 10.6% in 2020. GLP-1 RA users had higher total ($22,029 vs $15,165, P < 0.001), payer ($20,023 vs $13,758, P < 0.001), and out-of-pocket ($2,006 vs $1,407, P < 0.001) expenditures compared with nonusers. Multivariable GLMs indicated that GLP-1 RA users incurred an adjusted excess of $5,417 (P < 0.001), $4,764 (P < 0.001), and $436 (P = 0.001) for total, payer, and out-of-pocket expenditures, respectively. One in 13 adults used GLP-1 RAs. GLP-1 RA users had greater overall, third-party, and out-of-pocket expenditures. These findings underscore the growing economic impact of GLP-1 RA use and highlight the importance of developing strategies that balance the proven clinical advantages of GLP-1 RAs against their financial burden.
- 1 January 2026
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 32 (1) , 14-26
Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively reduce hypoglycemia and offer additional clinical benefits such as weight loss. However, their high costs impose a significant economic burden on both patients and payers. Health care expenditures associated with GLP-1 RA use have not been adequately examined in previous studies. To examine the excess expenditures (total, payer, and out-of-pocket) associated with GLP-1 RA use compared with nonuse among adults with diabetes in the United States. The study design was cross-sectional using data on adults (aged ≥18 years) with diabetes from multiple years (2016, 2018, and 2020) of the Medical Expenditure Panel Survey. Any GLP-1 RA use was derived from prescription medication files. Dependent variables included total, payer, and out-of-pocket health care expenditures. Excess expenditures associated with GLP-1 RAs were estimated using a multivariable generalized linear model (GLM) with gamma distribution and log link. The model adjusted for age, sex, race and ethnicity, social determinants of health, obesity, physical activity, and comorbid conditions. The study sample consisted of 7,670 adults with diabetes, representing approximately 28.6 million individuals in the United States. Overall, 7.5% of adults with diabetes used GLP-1 RAs, with rates increasing from 4.3% in 2016 to 10.6% in 2020. GLP-1 RA users had higher total ($22,029 vs $15,165, P < 0.001), payer ($20,023 vs $13,758, P < 0.001), and out-of-pocket ($2,006 vs $1,407, P < 0.001) expenditures compared with nonusers. Multivariable GLMs indicated that GLP-1 RA users incurred an adjusted excess of $5,417 (P < 0.001), $4,764 (P < 0.001), and $436 (P = 0.001) for total, payer, and out-of-pocket expenditures, respectively. One in 13 adults used GLP-1 RAs. GLP-1 RA users had greater overall, third-party, and out-of-pocket expenditures. These findings underscore the growing economic impact of GLP-1 RA use and highlight the importance of developing strategies that balance the proven clinical advantages of GLP-1 RAs against their financial burden.
- Open Access
- 3 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71176
Treatment Landscape for Older Men With Metastatic Hormone‐Sensitive Prostate Cancer in the United States
Objective: This study evaluated treatment patterns and factors associated with androgen deprivation therapy (ADT) intensification with androgen receptor pathway inhibitors (ARPI) and/or docetaxel among older men with mHSPC in the United States. Methods: The study utilized a retrospective cohort of 6850 older men (age ≥ 67 years) diagnosed with mHSPC between July 2016 and December 2019 from the Surveillance, Epidemiology, and End Results Medicare‐linked database. Men must maintain continuous enrollment in Medicare fee‐for‐service Parts A/B/D for ≥ 12 months before mHSPC diagnosis and ≥ 6 months after diagnosis. Initial treatment was classified as ADT alone, ADT + ARPI, or ADT + docetaxel. Factors associated with initial treatment were examined using multivariable multinomial logistic regression. Results: The study cohort (mean age = 76.6 years, SD = 7.0) was mostly non‐Hispanic white (77.7%), followed by non‐Hispanic Black (8.4%) and Hispanic (6.5%). 30.4% received no systemic drug therapy within 6 months of mHSPC diagnosis, 47.1% received ADT alone, 14.8% received ADT + ARPI, and 5.9% received ADT + docetaxel. Among men treated with ADT, there was an increase in ADT + ARPI treatment from 19.0% to 30.0% and a concomitant decline in ADT monotherapy from 72.1% to 62.6% between 2017 and 2019, while ADT + docetaxel treatment marginally decreased from 8.8% to 7.3%. In multinomial logistic regression, men with de novo mHSPC were more likely to receive ADT + docetaxel (aOR = 2.73, 95% CI = [2.07, 3.60]) or ADT + ARPI (aOR = 1.56, 95% CI = [1.32, 1.84]); whereas men with higher frailty index were less likely to receive ADT + docetaxel (aOR = 0.93, 95% CI = [0.91, 0.95]) or ADT + ARPI (aOR = 0.97, 95% CI = [0.96, 0.98]). Specifically, ADT + ARPI was less likely to be utilized among the lower socio‐economic status groups. Conclusions: Three in 10 older men with mHSPC received no systemic treatment. Although there was a gradual uptake of ARPIs, monotherapy with ADT was still highly prevalent, suggesting the integration of intensified treatment is still suboptimal. Targeted interventions are necessary to enhance guideline adherence among older and frail men with mHSPC.
- 3 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71176
Open AccessTreatment Landscape for Older Men With Metastatic Hormone‐Sensitive Prostate Cancer in the United States
Objective: This study evaluated treatment patterns and factors associated with androgen deprivation therapy (ADT) intensification with androgen receptor pathway inhibitors (ARPI) and/or docetaxel among older men with mHSPC in the United States. Methods: The study utilized a retrospective cohort of 6850 older men (age ≥ 67 years) diagnosed with mHSPC between July 2016 and December 2019 from the Surveillance, Epidemiology, and End Results Medicare‐linked database. Men must maintain continuous enrollment in Medicare fee‐for‐service Parts A/B/D for ≥ 12 months before mHSPC diagnosis and ≥ 6 months after diagnosis. Initial treatment was classified as ADT alone, ADT + ARPI, or ADT + docetaxel. Factors associated with initial treatment were examined using multivariable multinomial logistic regression. Results: The study cohort (mean age = 76.6 years, SD = 7.0) was mostly non‐Hispanic white (77.7%), followed by non‐Hispanic Black (8.4%) and Hispanic (6.5%). 30.4% received no systemic drug therapy within 6 months of mHSPC diagnosis, 47.1% received ADT alone, 14.8% received ADT + ARPI, and 5.9% received ADT + docetaxel. Among men treated with ADT, there was an increase in ADT + ARPI treatment from 19.0% to 30.0% and a concomitant decline in ADT monotherapy from 72.1% to 62.6% between 2017 and 2019, while ADT + docetaxel treatment marginally decreased from 8.8% to 7.3%. In multinomial logistic regression, men with de novo mHSPC were more likely to receive ADT + docetaxel (aOR = 2.73, 95% CI = [2.07, 3.60]) or ADT + ARPI (aOR = 1.56, 95% CI = [1.32, 1.84]); whereas men with higher frailty index were less likely to receive ADT + docetaxel (aOR = 0.93, 95% CI = [0.91, 0.95]) or ADT + ARPI (aOR = 0.97, 95% CI = [0.96, 0.98]). Specifically, ADT + ARPI was less likely to be utilized among the lower socio‐economic status groups. Conclusions: Three in 10 older men with mHSPC received no systemic treatment. Although there was a gradual uptake of ARPIs, monotherapy with ADT was still highly prevalent, suggesting the integration of intensified treatment is still suboptimal. Targeted interventions are necessary to enhance guideline adherence among older and frail men with mHSPC.
- Open Access
- 8 May 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102372
Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study
- 8 May 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102372
Open AccessUtilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study
- Open Access
- 29 December 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (1) , 26
Stress Due to Inflation and Its Association with Anxiety and Depression Among Working-Age Adults in the United States
Inflation generates stress, which may lead to high rates of anxiety and depression. Given the recent surge and subsequent decline in the inflation rate in the United States, the prevalence of stress due to inflation may vary, as well as its relationship with anxiety and depression. Therefore, we investigated the prevalence of stress due to inflation and its association with anxiety and depression over time among working-age adults in the United States. We conducted a repeated cross-sectional analysis using Household Pulse Survey (HPS) data for the following weeks: Week 50 (5–17 October 2022) and Week 57 (26 April–8 May 2023). The HPS includes questions about individuals’ stress levels due to price increases in the past two months. We used logistic regressions to examine the association of stress (moderate or high stress versus little or no stress) due to inflation with depression and anxiety among working-age adults controlling for several factors, including demographic factors and social determinants of health. From October 2022 to April–May 2023, the prevalence of stress due to inflation affected more than three quarters of the population (77.7% and 78.7%, respectively). In logistic regressions, we found a significant positive association of stress due to inflation with depression (adjusted odds ratio (AOR) [95% CI] = 2.22 [1.92, 2.57]) and anxiety (AOR [95% CI] = 2.50 [2.18, 2.86]). Despite a decline in the prevalence of both depression and anxiety by three percentage points over the study period, the associations between stress, due to inflation on the one hand, and anxiety and depression, on the other, persisted over time. Stress due to inflation affects more than three-quarters of Americans, and is significantly associated with depression and anxiety. Stress due to inflation is a significant and persistent public health issue.
- 29 December 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (1) , 26
Open AccessStress Due to Inflation and Its Association with Anxiety and Depression Among Working-Age Adults in the United States
Inflation generates stress, which may lead to high rates of anxiety and depression. Given the recent surge and subsequent decline in the inflation rate in the United States, the prevalence of stress due to inflation may vary, as well as its relationship with anxiety and depression. Therefore, we investigated the prevalence of stress due to inflation and its association with anxiety and depression over time among working-age adults in the United States. We conducted a repeated cross-sectional analysis using Household Pulse Survey (HPS) data for the following weeks: Week 50 (5–17 October 2022) and Week 57 (26 April–8 May 2023). The HPS includes questions about individuals’ stress levels due to price increases in the past two months. We used logistic regressions to examine the association of stress (moderate or high stress versus little or no stress) due to inflation with depression and anxiety among working-age adults controlling for several factors, including demographic factors and social determinants of health. From October 2022 to April–May 2023, the prevalence of stress due to inflation affected more than three quarters of the population (77.7% and 78.7%, respectively). In logistic regressions, we found a significant positive association of stress due to inflation with depression (adjusted odds ratio (AOR) [95% CI] = 2.22 [1.92, 2.57]) and anxiety (AOR [95% CI] = 2.50 [2.18, 2.86]). Despite a decline in the prevalence of both depression and anxiety by three percentage points over the study period, the associations between stress, due to inflation on the one hand, and anxiety and depression, on the other, persisted over time. Stress due to inflation affects more than three-quarters of Americans, and is significantly associated with depression and anxiety. Stress due to inflation is a significant and persistent public health issue.